China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent
There’s no definitive proof yet that Gilead’s remdesivir works as a treatment for 2019-nCov, but researchers in China clearly consider it promising enough to have applied for a patent on its use to combat the coronavirus virus outbreak stemming from Wuhan.
Amid worldwide vigilance over what many fear is becoming a pandemic, scientists from the Wuhan Institute of Virology and National Engineering Research Center for the Emergency Drug said they have tested a total of seven drugs in vitro — and found remdesivir and the malaria treatment chloroquine most effective against the novel coronavirus.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters